Entresto

sacubitril/valsartan
ARNI Novartis FDA Monitored

Safety Profile Overview

First-in-class angiotensin receptor-neprilysin inhibitor for heart failure. Reduced death and hospitalization versus enalapril in the PARADIGM-HF trial.

Generic Name
sacubitril/valsartan
Brand Names
Entresto
Therapeutic Class
ARNI
Manufacturer
Novartis

What Pharma Signal Tracks for Entresto

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Entresto Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Entresto.

curl "https://api.pharma-signal.com/drug/safety/entresto" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Entresto against other ARNI drugs, or explore the full manufacturer portfolio for Novartis.